The UAB Comprehensive Cancer will hold its first communitywide conference for young cancer survivors ages 15-39 on March 15.
Seventeen local artists will work with a variety of media to create masterpieces in 90 minutes that can be purchased during the silent auction.
Professor of Microbiology David Briles, Ph.D., and Professor of Optometry Lawrence DeLucas, O.D., Ph.D., will be inducted into the NIA, professional distinction accorded to academic inventors.
PNP Therapeutics, UAB and Southern Research Institute work abolishes otherwise unmanageable human cancers in preclinical rodent studies.
The new 1,600-square-foot Central Alabama High-Field Nuclear Magnetic Resonance Facility provides state-of-the-art sensitivity and resolution for biomedical research and drug discovery.
The University of Alabama System Board of Trustees approved the establishment of the James K. Kirklin, M.D., Endowed Lectureship and other faculty appointments during its Nov. 8 meeting.
Microbiology Professor John Kearney's research in monoclonal antibodies led to treatments for breast cancer, rheumatoid arthritis and more during his 40 years at UAB and earned him selection as the 2013 Distinguished Faculty Lecturer.
Yang’s research focuses on a new class of drug – PARP inhibitors – that interfere with a cancer cell’s ability to repair DNA damage, hastening cell death.
The UAB community came out to support the CPS-3, becoming the largest single site enrollment in the U.S. with 1,209 participants.